NASDAQ : CYPH
-$0.02 (-3.25%)
NASDAQ
Douglas E. Onsi
Asset Management
Financial Services
CYPH
6
US
USD
0.00
79.19
79.19
4.39
0.00
-$
0.00
0.83
-3.35
-0.12
$0.0682
$4.82M
0.00%
0.00%
23.83%
25.81%
1.04
0.00
0.00
$5.50
$5.50
$5.50
5/5
7 Analysts
-88.04%
4.48
2/9
$78.92M
$87.38M
$3M
-$56.75M
$65.74M
0.00
-1.16
27.28
-46.86%
-35.50%
-49.78%
-59.15%
0 days
| Name | Title |
|---|---|
| Will McEvoy | Chief Investment Officer & Director |
| Douglas E. Onsi | Chief Financial Officer, General Counsel, Treasurer & Secretary, President, Chief Executive Officer & Director |
No votes yet today — be the first to share your view!
About Cypherpunk Technologies Inc. (NASDAQ:CYPH) Stock
Cypherpunk Technologies Inc. is a privacy-focused technology company that combines a digital asset treasury strategy centered on Zcash (ZEC) with the development of novel cancer therapies through its subsidiary. The company's mission is to advance technologies that guarantee privacy for individuals on the internet, with a primary focus on investing in, accelerating the adoption of, and strengthening the ecosystem of Zcash, a privacy-preserving digital currency. ...
Cypherpunk Technologies Reports Second Quarter 2026 Financial Results
2026-08-12 07:05:00
CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the second quarter ended June 30, 2026.
Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research
2026-08-12 07:00:00
Peer-reviewed analyses establish baseline plasma DKK1 as a continuous quantitative biomarker predicting deepening sirexatamab benefit in 2L mCRC patients In DKK1-high 2L mCRC patients, sirexatamab improved response, progression-free survival, and overall survival when added to bevacizumab and chemotherapy CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Leap Therapeutics, Inc., the biotechnology subsidiary of Cypherpunk Technologies Inc. (Nasdaq: CYPH), today announced the publication of results from the randomized Phase 2 DeFianCe study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in Clinical Cancer Research.
Cypherpunk Technologies Inc. (CYPH) Shareholder/Analyst Call Prepared Remarks Transcript
2026-06-18 12:32:09
Cypherpunk Technologies Inc. (CYPH) Shareholder/Analyst Call Prepared Remarks Transcript
Cypherpunk Technologies Reports First Quarter 2026 Financial Results
2026-05-14 07:05:00
CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the first quarter ended March 31, 2026.
Frequently Asked Questions
What is the current Cypherpunk Technologies Inc. (CYPH) stock price?
Cypherpunk Technologies Inc.(NASDAQ:CYPH) stock price is $0.6579 in the last trading session. During the trading session, CYPH stock reached the peak price of $3.7 while $0.232 was the lowest point it dropped to. The percentage change in CYPH stock occurred in the recent session was --3.25% while the dollar amount for the price change in CYPH stock was -$0.02.
CYPH's industry and sector of operation?
The NASDAQ listed CYPH is part of Asset Management industry that operates in the broader Financial Services sector.
Who are the executives of CYPH?
Will McEvoy
| Chief Investment Officer & Director
Douglas E. Onsi
| Chief Financial Officer, General Counsel, Treasurer & Secretary, President, Chief Executive Officer & Director
|
|
|
How many employees does CYPH have?
Number of CYPH employees currently stands at 6. CYPH operates from 47 Thorndike Street, Cambridge, MA 02141, US.
Link for CYPH official website?
Official Website of CYPH is: https://www.cypherpunk.com
How do I contact CYPH?
CYPH could be contacted at phone #617 714 0360 and can also be accessed through its website. CYPH operates from 47 Thorndike Street, Cambridge, MA 02141, US.
How many shares of CYPH are traded daily?
The average number of CYPH shares traded daily for last 3 months was 3.81M.
What is the market cap of CYPH currently?
The market value of CYPH currently stands at $70.04M with its latest stock price at $0.6579